

## **SORRENTO THERAPEUTICS, INC.**

### **PROCESS FOR SECURITY HOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS**

Security holders of Sorrento Therapeutics, Inc. (“**Sorrento**”) wishing to communicate with Sorrento’s Board of Directors (the “**Board**”) or an individual director may send a written communication to the Board or such director c/o Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, Attn: Corporate Secretary.

Each communication must set forth the name and address of the Sorrento security holder(s) on whose behalf the communication is sent and the class, series and number of shares of Sorrento capital stock that are beneficially owned and of record by such security holder(s) as of the date of the communication. Each communication will be screened by Sorrento’s Corporate Secretary to determine whether it is appropriate for presentation to the Board or such director. Examples of inappropriate communications include junk mail, spam, mass mailings, product complaints, product inquiries, new product suggestions, resumes, job inquiries, surveys, business solicitations and advertisements, as well as unduly hostile, threatening, illegal, unsuitable, frivolous, patently offensive or otherwise inappropriate material.

Employees of Sorrento who wish to report a complaint or concern regarding accounting, internal accounting controls or auditing matters should refer to Sorrento’s Open Door Policy for Reporting Complaints Regarding Accounting, Auditing and Other Matters. Employees of Sorrento who wish to report a complaint or concern regarding any other matter, or who have questions regarding the Sorrento’s policies, practices or procedures, should refer to Sorrento’s Code of Conduct and Ethics.

This Process for Security Holders Communications with the Board (this “**Process**”) will be posted on Sorrento’s website at [www.sorrentotherapeutics.com](http://www.sorrentotherapeutics.com) and provided to any security holder of Sorrento who requests a copy by contacting the Corporate Secretary, Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121; (858) 203-4100.

This Process will be subject to the periodic review of the Board, which will be responsible for the review of the compliance procedures in place to implement this Process. Sorrento anticipates that modifications to this Process will be necessary from time to time as Sorrento’s needs and circumstances evolve, and as applicable legal or listing standards change. Sorrento reserves the right to amend, supplement or discontinue this Process and the matters addressed herein, without prior notice, at any time.

*Last Updated: March 15, 2019*